Research Alliance Corp III RACC
Drug Manufacturers - General, Healthcare
$10.10
−0.49%
- Market cap
- $91.9M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q2 FY26 |
|---|---|
| SG&A | $184.4K |
| −$184.4K | |
| Net income | $54K |
| $0.01 | |
| 1.4M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Research Alliance Corp III's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RACCResearch Alliance Corp III | $91.9M | n/m | n/a | n/m | n/m | n/m | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $45M | 4.0× | 3.3× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| Peer median | $455.9M | 11.4× | 13.5× | 1.3× | +7% | 11.6% |
More on Research Alliance Corp III
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .